跳至主要内容
临床试验/NCT01596829
NCT01596829终止2 期

Effect of Probiotic Formula on Reducing the Risk for Antibiotic-associated Diarrhoea

Danisco1 个研究点 分布在 1 个国家目标入组 258 人开始时间: 2012年12月1日最近更新:
适应症

试验速览

阶段
2 期
状态
终止
发起方
入组人数
258
试验地点
1
主要终点
Incidence of AAD

研究概览

简要总结

Antibiotic treatment disturbs the balance of the intestinal microbiota and predisposes to antibiotic associated diarrhea. Previous studies have shown that the risk of developing diarrhea during a course of antibiotics may be reduced by simultaneous consumption of probiotics. The aim of the present study is to assess the effect of a probiotic formula containing four strains on reducing the risk of antibiotic associated diarrhea.

详细描述

The aim of the study is to assess the effect of a probiotic formula on reducing the risk of antibiotic-associated diarrhea (AAD). The study will be conducted as a two-arm, parallel groups, placebo-controlled, double-blind, randomized clinical trial, stratified by age, gender and number of days on antibiotics. The duration of patient participation in the study will be up to 7 weeks (up to 3 weeks supplementation, 4 weeks follow-up). The overall duration of the study is expected to be approximately 8 months. Adult males and females that are prescribed antibiotic therapy for minimum of 3 and a maximum of 14 days will be included in the study. The incidence of AAD will be evaluated as the primary end-point. The stool from patients presenting diarrhea will be tested for the presence of Clostridium difficile and if negative for C. difficile, also for the presence of other common pathogens causing diarrhea. The overall microbiota will be analyzed from fecal samples taken regularly during each phase of the study.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Supportive Care
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Males and females aged 18-65 years.
  • Patients will be initiating antibiotic therapy.
  • The antibiotic therapy consists of one of the following: broad spectrum penicillins, cephalosporins, doxycycline, clarithromycin, ciprofloxacin or isoxazolyl penicillin.
  • The antibiotic therapy is expected to be 3 to 14 days in duration.
  • Obtained his/her informed consent after verbal and written information.
  • Have a high probability for compliance with and completion of the study.
  • Patients having a telephone available.
  • Body Mass Index between 19 and 30.

排除标准

  • Participation in a clinical trial with an investigational product or drug within the 60 days prior to screening.
  • Likeliness to be noncompliant with the protocol, or to be unsuitable to the study by the investigator for any reason.
  • Pregnant or breastfeeding women; women planning to become pregnant during the study months.
  • Presence of active diarrhea (3 or more loose or watery stools per 24 hour period).
  • Daily consumption of probiotics, fermented milk and/or yogurt with probiotics.
  • Known to have a previous reaction, including anaphylaxis, to any substance in composition of the study product (i.e. on-medicinal ingredients: Cellulose, hypromellose, magnesium stearate (vegetable source), ascorbic acid, Colloidal silicon dioxide).
  • Presence of an active, non-controlled intestinal disease such as Crohn's Disease or ulcerative colitis.
  • Regular use of proton pump inhibitors.
  • Bowel surgery, artificial heart valve, history of rheumatic heart disease or infective endocarditis.
  • A previous documented C. difficile infection < 3 months prior to study initiation.
  • Immunosuppressive therapy or any health condition causing immunosuppression (including haematological malignancies, AIDS).
  • Ongoing or recent use of antibiotic therapy in the 3 months prior to the study product first administration.
  • Planned administration of antibiotics other than broad spectrum penicillins, cephalosporins, doxycycline, ciprofloxacin or isoxazolyl penicillin for the treatment of an infection.
  • History of drug or alcohol abuse.

结局指标

主要结局

Incidence of AAD

时间窗: Up to 21 days

Incidence of diarrhoea defined as three or more loose or watery stools per a 24 h period.

次要结局

  • Duration of diarrhoea(Up to 21 days)
  • Fecal microbiota(Up to 21 days)
  • Safety profile(Up to 21 days)

研究者

发起方
Danisco
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验

Effect of Probiotic Formula on Reducing the Risk for... | 临床试验